Overview

• Zepbound, a weight loss drug by Eli Lilly, demonstrated up to 63% reduction in sleep apnea symptoms in recent trials.
• The drug, also known as tirzepatide, helped patients lose an average of 18% to 20% of their body weight over a year.
• Eli Lilly plans to seek FDA approval for Zepbound to treat sleep apnea, aiming for broader insurance coverage including Medicare.
• Studies indicate that Zepbound could be the first pharmaceutical treatment targeting the underlying disease of sleep apnea.
• High demand for weight loss drugs like Zepbound has led to shortages, affecting supply chains and patient access.